mechlorethamine has been researched along with Brill-Symmers Disease in 11 studies
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We reviewed all reported cases of Burkitt's lymphoma and/or Burkitt's leukemia (BLL) occurring following therapy for Hodgkin's disease." | 2.39 | Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease. ( Cooper, DL; Levy, A; Salloum, E; Tallini, G, 1996) |
| "The natural history of follicular lymphoma is believed not to have changed over the last 30 years." | 1.33 | New treatment options have changed the survival of patients with follicular lymphoma. ( Fisher, RI; LeBlanc, M; Maloney, DG; Miller, TP; Press, OW; Unger, JM, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (54.55) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Régis, A | 1 |
| Ben Salem, D | 1 |
| Lambert, A | 1 |
| Couaillier, JF | 1 |
| Casasnovas, O | 1 |
| Piard, F | 1 |
| Krausé, D | 1 |
| MOLANDER, DW | 1 |
| HALNAN, KE | 1 |
| RABENKO, J | 1 |
| CORREA URQUIZA, LM | 1 |
| Fisher, RI | 2 |
| LeBlanc, M | 1 |
| Press, OW | 1 |
| Maloney, DG | 1 |
| Unger, JM | 1 |
| Miller, TP | 1 |
| Longo, DL | 1 |
| Young, RC | 1 |
| Hubbard, SM | 1 |
| Wesley, M | 1 |
| Jaffe, E | 1 |
| Berard, C | 1 |
| DeVita, VT | 1 |
| Portlock, CS | 1 |
| Jurcic, JG | 1 |
| Koll, B | 1 |
| Brown, AE | 1 |
| Crown, JP | 1 |
| Yahalom, J | 1 |
| Gulati, SC | 1 |
| Salloum, E | 1 |
| Tallini, G | 1 |
| Levy, A | 1 |
| Cooper, DL | 1 |
| Solal-Céligny, P | 1 |
| Rywlin, AM | 1 |
| Recher, L | 1 |
| Hoffman, EP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma[NCT02008006] | Phase 2 | 21 participants (Actual) | Interventional | 2014-07-09 | Terminated (stopped due to Insufficient recruitment and unavailability of the treatment) | ||
| Ublituximab as Initial Therapy for Treatment-naive Follicular or Marginal Zone Lymphoma With Response-driven Addition of Umbralisib for Suboptimal Response[NCT04508647] | Phase 2 | 4 participants (Actual) | Interventional | 2020-11-23 | Completed | ||
| A Phase II Pilot Trial of CHOP Followed by Iodine-131-Labeled Monoclonal Anti-B1 Antibody for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas[NCT00003784] | Phase 2 | 102 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Number of subjects that reached a complete response at the end of single agent induction as defined by a Lugano score of 3 or less on arm MONO - Monotherapy: Ublituximab.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake.~Patients who did not reach complete response at this point were then bridged to arm COMBO - Combotherapy: Ublituximab + Umbralisib." (NCT04508647)
Timeframe: 8 weeks post induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Ublituximab Only | 2 |
"Number of subjects that reached a complete response at up to 12 months post induction as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake." (NCT04508647)
Timeframe: up to 12 months post induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Ublituximab Only | 2 |
| Ublituximab First, Then Ublituximab and Umbralisib | 2 |
"Overall Response Rate for number of subjects as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Overall response rate assessed via PET CT utilizing Lugano deauvile criteria where lymphoma lesions had responded and would include complete response, partial response (> 50% improvement) and stable disease (less than 50 % response)" (NCT04508647)
Timeframe: up to 12 months post induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Ublituximab Only | 2 |
| Ublituximab First, Then Ublituximab and Umbralisib | 2 |
2 reviews available for mechlorethamine and Brill-Symmers Disease
| Article | Year |
|---|---|
Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Cyclophosphamide | 1996 |
[Follicular lymphomas. Therapeutic indications].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1992 |
9 other studies available for mechlorethamine and Brill-Symmers Disease
| Article | Year |
|---|---|
[Concomitant pulmonary Langerhans cell histiocytosis and malignant lymphoma: report of two cases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bleomycin; Combined Modality Therapy; | 2009 |
THE MALIGNANT LYMPHOMAS.
Topics: Adrenal Cortex Hormones; Chlorambucil; Cyclophosphamide; Hodgkin Disease; Humans; Lymphoma; Lymphoma | 1963 |
LONG-TERM RESULTS OF X-RAY TREATMENT IN MALIGNANT DISEASE OF THE LYMPHO-RETICULAR SYSTEM.
Topics: Classification; England; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodg | 1964 |
[The use of nitrogen mustard in the treatment of lymphatic diseases of a malignant type].
Topics: Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, | 1959 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
Prolonged initial remission in patients with nodular mixed lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1984 |
Deferral of initial therapy for advanced indolent lymphomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therap | 1982 |
Excretion of Ascaris lumbricoides during total body irradiation.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascariasis; Ascaris lumbricoides; Bo | 1994 |
Lymphoma-like presentation of Kaposi's sarcoma. Three cases without characteristic skin lesions.
Topics: Aged; Blood; Blood Protein Electrophoresis; Diagnosis, Differential; Female; Hodgkin Disease; Humans | 1966 |